ISPOR - Therapy Escalation Thresholds and the Potential for Biased Cost Effectiveness Analysis When Failing to Sample Baseline HbA1c in Type 2 Diabetes

Full Text

Therapy Escalation Thresholds and the Potential for Biased Cost Effectiveness Analysis When Failing to Sample Baseline HbA1c in Type 2 Diabetes

Abstract

Authors

P. McEwan V. Foos J.L. Palmer M. Lamotte D. Grant

Back to Volume 16, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now